Genentech, Inc.

Is Genentech owned by Roche?

Yes. Genentech is a wholly owned subsidiary of Roche Holding AG. Roche first acquired majority control in 1990 for $2.1 billion and completed the purchase of remaining shares in March 2009 for approximately $46.8 billion.

When was Genentech founded?

Genentech was founded in April 1976 in South San Francisco, California. It is widely credited as the company that founded the biotechnology industry.

Who founded Genentech?

Robert Swanson, a venture capitalist, and Herbert Boyer, a UCSF biochemist who co-invented recombinant DNA technology, founded the company. Each contributed $500 in seed capital.

Is Genentech publicly traded?

No. Genentech traded on the NYSE as DNA until its full acquisition by Roche in March 2009. Parent company Roche trades on the SIX Swiss Exchange under ROG.

How many employees does Genentech have?

Approximately 12,100, concentrated at its South San Francisco headquarters campus and manufacturing sites in California and Oregon. Multiple rounds of layoffs between 2024 and 2025 reduced the workforce by more than 700 positions.

What are Genentech's biggest products?

Its leading current products include Ocrevus for multiple sclerosis, Hemlibra for hemophilia A, Vabysmo for retinal disease, and Tecentriq for cancer. Legacy products Herceptin, Avastin, and Rituxan remain significant but face biosimilar competition.

Genentech began in April 1976 when Robert Swanson, a 28-year-old venture capitalist at Kleiner Perkins, persuaded UCSF biochemist Herbert Boyer that recombinant DNA technology could produce human proteins industrially. Boyer had developed the gene-splicing technique with Stanley Cohen of Stanford in 1973, and the two founders each contributed $500 to incorporate the company.

The first laboratory operated from a rented warehouse in South San Francisco. Within two years Genentech scientists had produced somatostatin, the first human protein made in bacteria, and in 1978 achieved synthetic human insulin, which Eli Lilly licensed and marketed as Humulin beginning in 1982. Genentech's October 1980 IPO became a Wall Street sensation when shares priced at $35 climbed as high as $88 on the first trading day.

Through the 1980s the company launched Protropin (recombinant growth hormone, 1985), Activase (tPA for heart attacks, 1987), and Nutropin. The near-failure of Activase to meet commercial expectations strained finances, and in February 1990 Roche Holding purchased a majority interest for $2.1 billion, an alliance that preserved Genentech's operational independence while providing financial security.

The 1997 approval of Rituxan, the first monoclonal antibody for cancer, began a franchise that redefined the company. Herceptin (1998) and Avastin (2004) followed, making Genentech the dominant force in oncology biologics. By the mid-2000s these three products generated more than $10 billion in combined annual sales.

Roche moved to full ownership in 2008, initially facing resistance from Genentech's board, which negotiated the price from $89 to $95 per share before the $46.8 billion deal closed in March 2009. Genentech's campus became the headquarters for Roche's US pharmaceutical operations, and the companies merged their American commercial organizations while keeping early research separate.

Post-merger approvals include Ocrevus and Hemlibra in 2017, Tecentriq line extensions, Vabysmo in 2022, and bispecific antibodies Columvi and Lunsumio. The company faced the patent cliff of its legacy oncology trio through the 2020s as biosimilars entered the US market. Between 2024 and 2025, Genentech executed multiple rounds of layoffs totaling more than 700 positions as part of a Roche-wide cost restructuring, while simultaneously committing $700 million to a new Holly Springs, North Carolina manufacturing site for its obesity medicine pipeline.

Genentech operates under Roche's group sustainability commitments, which include science-based emissions reduction targets and a goal of net zero operations. Manufacturing sites in California have invested in renewable electricity, water recycling, and solvent recovery programs.

The company runs one of the industry's larger patient assistance programs, providing free medicines to qualifying patients who lack insurance coverage. Its access practices nonetheless attract the pricing scrutiny applied across branded pharma, particularly for specialty medicines with six-figure annual list prices.

Genentech has appeared on Fortune's 100 Best Companies to Work For list for more than 25 consecutive years, one of the longest continuous runs on the ranking. Science magazine has repeatedly named it a top employer in its annual survey of life sciences companies.

Its research heritage has produced Lasker Awards, Breakthrough Prizes, and other scientific honors for work in recombinant DNA technology and antibody therapeutics, and its community programs in South San Francisco have earned regional civic recognition.

Genentech resolved a federal investigation in 1999 related to its marketing of Protropin, paying $50 million in one of the earliest major pharmaceutical marketing settlements. In 2009 it paid $20 million to resolve allegations concerning Rituxan promotion.

The FDA's 2011 withdrawal of Avastin's breast cancer indication, after a contested advisory process, became a landmark debate over accelerated approval standards. The company also faced sustained criticism of US pricing for its oncology products through the 2010s.

Workforce reductions since 2024, exceeding 700 positions, have drawn local press scrutiny of Genentech's long-term commitment to its South San Francisco campus, though the company simultaneously committed to the $700 million North Carolina facility as part of portfolio rebalancing.